MEK inhibition suppresses cell invasion and migration in ovarian cancers with activation of ERK1/2

Katagiri,Atsuko; Nakayama,Kentaro; Rahman,Mohammed Tanjimur; Rahman,Munmun; Yeasmin,Shamina; Ishikawa,Masako; Iida,Kouji; Nakayama,Naomi; Miyazaki,Khoji

doi:10.3892/etm_00000093

MEK inhibition suppresses cell invasion and migration in ovarian cancers with activation of ERK1/2

Authors:
- Atsuko Katagiri
- Kentaro Nakayama
- Mohammed Tanjimur Rahman
- Munmun Rahman
- Shamina Yeasmin
- Masako Ishikawa
- Kouji Iida
- Naomi Nakayama
- Khoji Miyazaki
View Affiliations

Affiliations: Departments of Obstetrics and Gynecology, Shimane University School of Medicine, Shimane 6938501, Japan
Published online on: July 1, 2010 https://doi.org/10.3892/etm_00000093
Pages: 591-596

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The extracellular-regulated kinase (ERK) signaling pathway plays an important role in regulating the malignant potential of a cancer cell. However, the effect of ERK signaling on cancer metastasis is not clearly understood. In the present study, we examined the status of ERK activation in 88 ovarian carcinomas in order to clarify the clinicopathological and prognostic significance of phosphorylated ERK1/2 (p-ERK1/2). p-ERK1/2 expression was identified in 37 (42%) of 88 ovarian carcinomas. There was no significant correlation between p-ERK1/2 expression and any of the clinicopathological factors tested. No significant correlation between p-ERK1/2 expression and overall survival was found in patients with ovarian carcinoma treated with platinum and taxane chemotherapy (P=0.426). Next, to clarify the role of ERK1/2 activation in ovarian cancers, we inactivated ERK1/2 in ovarian cancer cells using the MEK inhibitor, CI-1040, which prevents ERK1/2 activation. Based on simulated wound healing and invasion chamber assays, we found that the motility and invasion of ES2 and MPSC1 cells with p-ERK1/2 were significantly reduced (P<0.01) after treatment with CI-1040. By contrast, CI-1040 did not have any effect on KF28 cells, which were negative for p-ERK1/2. Twist was down-regulated simultaneously with p-ERK1/2 following treatment of ES2 and MPSC1 cells with CI-1040. Immunohistochemistry of ovarian carcinoma tissue revealed that the increased expression of p-ERK1/2 significantly correlated with Twist expression (P<0.01). The findings in this study provide new insight into the biological role of ERK signaling in ovarian carcinomas. Additionally, our observations have an important therapeutic implication for patients with ovarian cancers that express p-ERK1/2 as these patients may potentially benefit from CI-1040 therapy.

View Figures

View References

1.	Wingo PA, Tong T and Bolden S: Cancer statistics, 1995. CA Cancer J Clin. 45:8–30. 1995. View Article : Google Scholar
2.	Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D and Lopes CS: Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol. 15:1535–1542. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Singer G, Oldt R III, Cohen Y, et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 95:484–486. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Nakayama K, Nakayama N, Kurman RJ, et al: Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther. 5:779–785. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Wan PT, Garnett MJ, Roe S, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Olson JM and Hallahan AR: p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med. 10:125–129. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Hsu CY, Bristow R, Cha MS, et al: Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res. 10:6432–6436. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Peyssonnaux C and Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 93:53–62. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Allen LF, Sebolt-Leopold J and Meyer MB: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol. 30:105–116. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Yamamoto K, Kikuchi Y, Kudoh K and Nagata I: Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol. 126:168–172. 2000. View Article : Google Scholar : PubMed/NCBI
11.	Holmstrom TH, Tran SE, Johnson VL, et al: Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol Cell Biol. 19:5991–6002. 1999.PubMed/NCBI
12.	Cowley GP and Smith ME: Modulation of E-cadherin expression and morphological phenotype in the intravascular component of adenocarcinomas. Int J Cancer. 60:325–329. 1995. View Article : Google Scholar : PubMed/NCBI
13.	Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. J Cell Sci. 117:4619–4628. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Mansour SJ, Matten WT, Hermann AS, et al: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 265:966–970. 1994. View Article : Google Scholar : PubMed/NCBI
15.	Mansour SJ, Resing KA, Candi JM, et al: Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis. J Biochem. 116:304–314. 1994.
16.	Anand-Apte B, Zetter BR, Viswanathan A, et al: Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways. J Biol Chem. 272:30688–30692. 1997. View Article : Google Scholar
17.	Klemke RL, Cai S, Giannini AL, et al: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 137:481–492. 1997. View Article : Google Scholar : PubMed/NCBI
18.	Webb DJ, Donais K, Whitmore LA, et al: FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol. 6:154–161. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Cheresh DA, Leng J and Klemke RL: Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J Cell Biol. 146:1107–1116. 1999. View Article : Google Scholar : PubMed/NCBI
20.	Lai CF, Chaudhary L, Fausto A, et al: Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem. 276:14443–14450. 2001.PubMed/NCBI
21.	Mao TL, Seidman JD, Kurman RJ and Shih IM: Cyclin E and p16 immunoreactivity in epithelioid trophoblastic tumor – an aid in differential diagnosis. Am J Surg Pathol. 30:1105–1110. 2006.PubMed/NCBI
22.	Mizumoto Y, Kyo S, Mori N, et al: Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 98:652–658. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Nakayama N, Nakayama K, Yeasmin S, et al: KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer. 99:2020–2028. 2008. View Article : Google Scholar : PubMed/NCBI
24.	Kang Y and Massague J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
25.	Terauchi M, Kajiyama H, Yamashita M, et al: Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma. Clin Exp Metastasis. 24:329–339. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Niu RF, Zhang L, Xi GM, et al: Up-regulation of Twist induces angiogenesis and correlates with metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 26:385–394. 2007.PubMed/NCBI
27.	Mironchik Y, Winnard PT, Vesuna F, et al: Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 65:10801–10809. 2005. View Article : Google Scholar : PubMed/NCBI
28.	Maestro R, Dei Tos AP, Hamamori Y, et al: Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 13:2207–2217. 1999. View Article : Google Scholar : PubMed/NCBI
29.	Chou FL, Hill JM, Hsieh JC, et al: PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation. J Biol Chem. 278:52587–52597. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Kurata H, Thant AA, Matsuo S, et al: Constitutive activation of MAP kinase kinase (MEK1) is critical and sufficient for the activation of MMP-2. Exp Cell Res. 254:180–188. 2000. View Article : Google Scholar : PubMed/NCBI
31.	Webb DJ, Nguyen DH and Gonias SL: Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and Matrigel invasion. J Cell Sci. 113:123–134. 2000.
32.	Takino T, Miyamori H, Watanabe Y, et al: Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res. 64:1044–1049. 2004. View Article : Google Scholar
33.	Tanigawara Y, Kita T, Hirono M, et al: Identification of N-acetyltransferase 2 and CYP2C19 genotypes for hair, buccal cell swabs, or fingernails compared with blood. Ther Drug Monit. 23:341–346. 2001. View Article : Google Scholar : PubMed/NCBI
34.	Sebolt-Leopold JS, Dudley DT, Herrera R, et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 5:810–816. 1999. View Article : Google Scholar : PubMed/NCBI
35.	Arteaga CL and Baselga J: Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? Cancer Cell. 5:525–531. 2004. View Article : Google Scholar : PubMed/NCBI
36.	Rinehart J, Adjei AA, Lorusso PM, et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon and pancreatic cancer. J Clin Oncol. 22:4456–4462. 2004. View Article : Google Scholar : PubMed/NCBI